Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
What is the dark side of GLP-1
Physical address is not on the public site
News provided by Novo Nordisk May 07, 2026, 07:00 ET Eligible Medicare patients living with obesity will have access to Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major CV events such as death, heart attack, or stroke in adults living with obesity with known heart disease, a claim only Wegovy can make Novo Nordisk's participation in the Medicare GLP-1 Bridge expands patient access to authentic, FDA-approved Wegovy PLAINSBORO, N.J., May 7, 2026 /PRNewswire/ -- The Medicare GLP-1 Bridge will provide eligible Medicare beneficiaries living with obesity access to Wegovy (semaglutide) injection and tablets for a $50 monthly copay , beginning July 1, 2026, per yesterday's announcement from the Centers for Medicare & Medicaid Services (CMS)
The adoption rate is even higher among the largest employers, where 43% of companies with 5,000 or more workers provide coveragea significant jump from 28% in 2024
Like many people struggling with weight loss, I wanted something that seemed newer and more effective than traditional medications
US$ 28.21
US$ 29.41
US$ 24.22
